PD-L1单抗Imfinzi-话题@MedSci

#PD-L1单抗Imfinzi#

6篇内容 | 827人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1455213, encodeId=411d145521376, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, objectTitle=PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌, objectType=article, longId=199855, objectId=787719985534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=787719985534, replyNumber=0, likeNumber=35, createdTime=2020-08-24, rootId=0, userName=lidong42, userId=80615636733, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=787719985534, moduleTitle=PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=787719985534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455212, encodeId=4f8e145521260, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, objectTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, objectType=article, longId=191241, objectId=eff619124151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eff619124151, replyNumber=0, likeNumber=29, createdTime=2020-04-03, rootId=0, userName=lidong42, userId=80615636733, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eff619124151, moduleTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eff619124151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455211, encodeId=15e6145521124, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, objectTitle=FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查, objectType=article, longId=183990, objectId=e516183990ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e516183990ae, replyNumber=0, likeNumber=44, createdTime=2019-12-04, rootId=0, userName=lidong42, userId=80615636733, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e516183990ae, moduleTitle=FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e516183990ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455210, encodeId=780c145521006, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定, objectType=article, longId=175359, objectId=a0671e535994, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0671e535994, replyNumber=0, likeNumber=32, createdTime=2019-07-14, rootId=0, userName=lidong42, userId=80615636733, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0671e535994, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0671e535994)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455209, encodeId=97c01455209ac, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, objectType=article, longId=174364, objectId=c1da1e436402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e436402, replyNumber=0, likeNumber=38, createdTime=2019-06-29, rootId=0, userName=lidong42, userId=80615636733, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e436402, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e436402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455208, encodeId=895f1455208e6, content=<a href='/topic/show?id=b1e81392524' target=_blank style='color:#2F92EE;'>#PD-L1单抗Imfinzi#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, objectType=article, longId=149623, objectId=297e149623e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297e149623e6, replyNumber=0, likeNumber=26, createdTime=2018-09-27, rootId=0, userName=lidong42, userId=80615636733, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297e149623e6, moduleTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297e149623e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1单抗Imfinzi

2020-05-29

lidong42 (审核中...)

前往app查看评论内容

#PD-L1单抗Imfinzi#

PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌

2020-08-24

lidong42 (审核中...)

前往app查看评论内容

#PD-L1单抗Imfinzi#

FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗

2020-04-03

lidong42 (审核中...)

前往app查看评论内容

#PD-L1单抗Imfinzi#

FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查

2019-12-04

lidong42 (审核中...)

前往app查看评论内容

#PD-L1单抗Imfinzi#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定

2019-07-14

lidong42 (审核中...)

前往app查看评论内容

#PD-L1单抗Imfinzi#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点

2019-06-29

lidong42 (审核中...)

前往app查看评论内容

#PD-L1单抗Imfinzi#

阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌

2018-09-27

科室
- - 订阅+
  - 更多科室
工具
服务